A substitute machine is a different named intervention, not leftover package sessions
Ask for the substitute machine’s named identity before you accept leftover package sessions as the same treatment. When a clinic’s scheduled laser is down, remaining prepaid sessions are sometimes moved onto another console in the same facility. That offer treats a package as leftover inventory. For the patient, it is a change in named-device identity, candidacy, and consent.
Reconstruct, as separate fields, the scheduled device’s trade name and model; the substitute device’s trade name and model; each device’s intended-use and patient-population language if a 510(k) summary or other public clearance record is known; who will reassess candidacy and obtain consent for the device that will actually be used; and what the written package says about unused sessions. Those five questions still stand even if both machines are called lasers, share a wavelength band, or come from the same manufacturer family.
This article is a patient question worksheet for a mid-package equipment change after downtime. It is not a wavelength comparison, not a patch-test protocol, not membership accounting, not a used-laser buying guide, not a 510(k) lookup tutorial, not off-label consent documentation, not a treatment-stacking safety protocol, and not a request for copies of notes already created. Adjacent AestheticMedGuide pages already own those jobs: how laser and intense pulsed light differ; how to verify an aesthetic device’s 510(k) clearance; informed consent for off-label aesthetic treatments; how to request existing treatment records; clinic laser hair-removal patch-test documentation; due diligence when buying a used aesthetic laser; clinic laser maintenance and shot-count logs; whether treatment memberships are worth it; med-spa membership accounting and refund exposure; and combination-procedure timing and stacking safety. This page does not retell them.
Scheduled-device identity: What trade name, model, manufacturer, and, if known, 510(k) or other clearance identifier named the machine that was assessed and consented to?
Substitute-device identity and indication match: What trade name and model name the replacement, and do its intended-use and patient-population statements—where a public 510(k) summary exists—match the indication and population context that were planned, or is that match unknown?
Clinician reassessment: Who will reassess candidacy for the device that will actually be used, and is that person named?
Consent for the device actually used: Is consent being sought for that specific intervention, including its nature, purpose, burdens, risks, expected benefits, and the option of forgoing treatment, rather than reused from the original booking?
Written package terms: What written language, if any, covers unused sessions, expiration, substitution, or pause, and which of those fields remain blank?
MedDeviceRepair is a publication covering medical equipment service records. It is not a service contractor, regulator, or source of clearance. As related reading, MedDeviceRepair’s overview of medical equipment service record requirements explains why a closed work order names the unique device that was inspected or repaired. That page is adjacent healthcare technology management (HTM) identity reading. It is not a finding that a different laser fits the patient’s skin or indication, and it is not cited as an authority in this article’s sources.
Citations to Title 21 below use the unofficial eCFR. The Title 21 display used here was current as of 4 September 2026; Title 21 was last amended 31 August 2026. Absence of a field in a given 510(k) summary must be recorded as unknown. This worksheet does not invent mix-up rates, typical substitution frequency, refund rates, energy settings, or real patient cases.
What a 510(k) summary still has to name
The public legal baseline for treating a substitute console as a different named device is 21 CFR 807.92, which states what a 510(k) summary must contain for one device. It does not enumerate how clinics document mid-package substitutions, and it does not create interchangeability among separately named devices.
Under 21 CFR 807.92(a), every 510(k) summary must include, among other elements:
Device name — 21 CFR 807.92(a)(2): the name of the device, including the trade or proprietary name if applicable, the common or usual name, and the classification name, if known. Paragraph (a)(1) is the submitter’s name, address, telephone number, contact person, and the date the summary was prepared—not the device name.
Predicate — 21 CFR 807.92(a)(3): an identification of the legally marketed device to which the submitter claims equivalence.
Device description — 21 CFR 807.92(a)(4): a description of the subject device, including how it functions, the scientific concepts that form its basis, and significant physical and performance characteristics, such as design, material used, and physical properties.
Intended use and patient population — 21 CFR 807.92(a)(5): a statement of intended use, including a general description of the diseases or conditions the device will diagnose, treat, prevent, cure, or mitigate, including a description, where appropriate, of the patient population for which the device is intended. Patient-population language is required where appropriate; if a given summary omits it, record that field as unknown rather than inventing phototype or anatomical limits.
Technological characteristics — 21 CFR 807.92(a)(6): a summary of technological characteristics compared with the predicate, including design, material, chemical composition, and energy source. If characteristics differ from the predicate, the summary must compare them to the legally marketed device identified in paragraph (a)(3).
Those fields are why two machines that share a wavelength band or an indication category remain separate named products unless the public 510(k) summary shows they are the same named device. A clinic statement that both are “1064 lasers,” or that they sit in the same manufacturer family, does not collapse two summaries into one intervention. Once a trade name is known, the published 510(k) lookup article is the place to search a K-number; this worksheet only tells you which identity fields to request, not how to run that search.
21 CFR 807.92 does not itself list clinic package terms, interchangeability among separately cleared lasers, or a duty for a treatment room to file a 510(k). It is the public format for one device’s summary.
Clearance is not approval and is not interchangeability
A common misunderstanding is that if a substitute machine is “cleared by the FDA,” it has been approved as interchangeable with any other cleared machine in its class. 21 CFR 807.97 does not say that, and it does not define clinical interchangeability. What it does say is narrower and still material.
21 CFR 807.97 states that submission of a premarket notification and a subsequent determination of substantial equivalence do not in any way denote official approval of the device. Any representation that creates an impression of official approval because the device complied with the premarket-notification regulations is misleading and constitutes misbranding. Clearance of a substitute laser is therefore not FDA approval, and it is not, by itself, proof the substitute is interchangeable with the scheduled device.
The FDA Premarket Notification 510(k) page, content current as of 22 August 2024, is an agency explainer, not a substitute for 21 CFR 807 Subpart E. It states that a device is substantially equivalent if, in comparison to a predicate, it has the same intended use and any differences in technological characteristics do not raise different questions of safety and effectiveness. A claim of substantial equivalence does not mean the new and predicate devices need to be identical. Until the submitter receives an order declaring the device substantially equivalent, the submitter may not market the device. That is a manufacturer-to-FDA marketing-clearance rule for one named device. It is not a finding that two separately cleared lasers may be substituted for one another in a prepaid package, and it is not a clinic filing duty.
When a clinic substitutes a device, it is introducing a unit whose 807.92 identity, intended-use, and technological-characteristic fields may differ from the scheduled unit. Substantial equivalence answers a marketing-clearance question against a predicate. It does not answer whether remaining package sessions are the same intervention.
Manufacturer labeling-change rules are not a clinic 510(k)
21 CFR 807.81(a) applies to each person required to register who proposes to introduce a device into commercial distribution. Paragraph (a)(3) requires a premarket notification when a device the person currently has in commercial distribution is about to be significantly changed or modified in design, components, method of manufacture, or intended use. Significant changes include a change that could significantly affect safety or effectiveness and a major change or modification in intended use. Those are manufacturer obligations for the labeled device that firm markets. A clinic’s decision to finish a patient’s remaining sessions on a different console is not a manufacturer 510(k) amendment.
Paragraph (b)(1)(ii) excepts a change consistent with a predetermined change control plan (PCCP) cleared under section 515C of the Federal Food, Drug, and Cosmetic Act, provided the change is consistent with that plan. A PCCP is a manufacturer cleared-plan rule. It does not describe clinic substitutions and does not authorize a treatment-room swap.
The agency’s October 25, 2017 guidance Deciding When to Submit a 510(k) for a Change to an Existing Device represents current FDA thinking. FDA guidance documents, including this one, do not establish legally enforceable responsibilities. They should be viewed only as recommendations unless a specific regulatory or statutory requirement is cited. The word should in Agency guidance means that something is suggested or recommended, but not required. The PDF retrieved for this article includes a February 2, 2024 Quality Management System Regulation cover note. The guidance is a manufacturer labeling-and-design-change framework under 21 CFR 807.81(a)(3), not a clinic duty to file a 510(k) when a treatment room is down.
The same guidance defines indications for use, citing 21 CFR 814.20(b)(3)(i), as the disease or condition the device will diagnose, treat, prevent, cure, or mitigate, including a description of the patient population for which the device is intended, and states that the indications include all the labeled patient uses of the device. Question A.1.4 asks whether a labeling change describes a new disease, condition, or patient population; such a change likely requires a new 510(k) from the manufacturer.
Direction-for-use examples that, in the guidance, can significantly affect safety or effectiveness include adding a new procedural technique not described in the original labeling; use of a product for a duration or frequency different from the cleared labeling; and adding instructions for device use in a new patient population not described in the original indications for use.
Those examples are evidence that FDA does not treat two lasers that share a wavelength or indication category as the same labeled intervention for the manufacturer. They are not a clinic 510(k) filing instruction, and they are not a finding that a patient’s remaining package sessions may continue unchanged on a substitute machine. This article does not convert the 2017 guidance into operating parameters, test-spot intervals, or energy settings.
A clinic's oral 'same treatment' claim does not rewrite intended use
21 CFR 801.4 defines intended uses as the objective intent of the persons legally responsible for the labeling of an article (or their representatives). That intent may be shown by labeling claims, advertising, or oral or written statements by those persons or their representatives. A clinic employee’s oral claim that a substitute machine is the same treatment does not rewrite the substitute device’s labeled intended use. The people legally responsible for labeling are not, by that regulation, the front-desk staff repeating a backup-console script.
The same section states that a firm is not regarded as intending an unapproved new use solely because it knows health-care providers prescribed or used the device for that use. Manufacturer knowledge of off-label clinician use is not itself a new 510(k). Off-label clinic use remains a consent and reassessment question rather than an automatic manufacturer filing event. If a packer, distributor, or seller intends different uses than the person from whom the article was received, that party must supply adequate labeling for the new intended uses—another manufacturer or distributor labeling rule, not a patient refund statute.
If the substitute will be used outside the labeled intended use, that is not an administrative continuation of the original booking. It is a different intervention whose nature, purpose, burdens, risks, expected benefits, and option of forgoing treatment still need to be presented. The published off-label aesthetic consent article documents that job. This worksheet only flags that off-label use cannot be slipped in as leftover package sessions.
A labeled fictional illustration, not a real case: suppose scheduled Console A’s public summary, where it exists, states a patient population that includes the planned indication, and substitute Console B’s public summary is silent on patient population or states a different population. The match is unknown or unmatched until the treating clinician names both devices and explains the labeled intended use of the machine that will actually be used. Do not invent Fitzpatrick ranges, anatomical zones, or clearance identifiers that are not on the summary in front of you.
Consent was for a specific intervention
AMA Code of Medical Ethics Opinion 2.1.1 is professional ethics guidance for physicians. It is not a statute, not a state med-spa regulation, and not a federal cancellation right. It does not itself assign duties to every non-physician laser operator. The worksheet still requires the responsible clinician to be named rather than inventing a universal operator rule. Emergency exceptions in the Opinion do not apply to elective aesthetic package sessions.
Opinion 2.1.1 states that informed consent to medical treatment is fundamental in both ethics and law, and that patients have the right to receive information and ask questions about recommended treatments so they can make well-considered decisions about care. The process occurs when communication between a patient and physician results in the patient’s authorization or agreement to undergo a specific medical intervention.
In seeking informed consent, physicians should, among other duties:
Assess capacity: assess the patient’s ability to understand relevant medical information and the implications of treatment alternatives and to make an independent, voluntary decision.
Present information: present relevant information accurately and sensitively, including the diagnosis when known; the nature and purpose of recommended interventions; and the burdens, risks, and expected benefits of all options, including forgoing treatment.
Document: document the informed-consent conversation and the patient’s (or surrogate’s) decision in the medical record. When specific written consent has been provided, the consent form should be included in the record.
Consent given for the scheduled laser is therefore not automatically consent for a different device, modality, indication, or operator. A labeled fictional illustration, not a real case: a consent document that names one scheduled console does not, by itself, authorize a different named laser or an intense pulsed light system, even if both sit in the same hallway. If the clinic cannot name the responsible clinician who will reassess candidacy and obtain consent for the device actually used, that field stays unknown.
The FDA Aesthetic (Cosmetic) Devices page, content current as of 7 December 2022, tells people considering an aesthetic procedure to talk with their health-care provider about benefits and risks associated with aesthetic devices, discuss whether they are a candidate, fully understand the benefits and risks, and consider asking about the provider’s training and experience with the procedure. Effects may be temporary, a procedure may not give the desired result, and there are risks when using any device, including aesthetic devices. A downtime substitution still requires that candidacy conversation for the device that will actually be used, including who will operate it. The page does not define interchangeability, mix-up rates, or package-refund rights, and it does not quantify operator hours on a backup console.
This worksheet does not prescribe universal clinical dosing, test-spot intervals, or energy settings. Those decisions require individualized evaluation by the responsible clinician. If identity, indication match, or consent owner is unknown, the unresolved choice is whether to proceed, pause, or decline—not an assumed yes.
Service paperwork names the down unit; package terms are a separate owner
When equipment is down, staff may show a service ticket, invoice, or work order. Ask which unique device that paperwork names. As related reading, MedDeviceRepair’s service-record requirements article treats a closed work order as release evidence for the unique device inspected or repaired, matching manufacturer, model, and serial to the nameplate. That is identity reading for the unit that was serviced. It is not a promise of clinical efficacy, and it does not evaluate whether a different console is suitable for the patient’s skin or indication.
Service or maintenance paperwork for the original unit explains, at most, why that serial-numbered machine is out of service. Paperwork for the substitute unit, if it exists, names that different asset. Neither record answers suitability. Clinic capital and HTM log questions belong to buying a used aesthetic laser and laser maintenance-log and shot-count documentation; they are not this patient’s handover.
Prepaid aesthetic packages are private commercial contracts governed by the written terms signed at purchase and by applicable state contract law. This article does not advise that a named clinic must refund unused sessions, and it does not treat 16 CFR Part 429 as an automatic cancellation right for an in-clinic package purchase. Whether unused sessions may be paused, extended, credited, or forfeited is a written-contract field. If that field is blank, it stays unknown.
The clinic’s administrative owner of unused sessions is a different role from the clinician who must reassess candidacy. Membership value, deferred-revenue accounting, and combination-procedure timing are separate published jobs: treatment memberships, membership-program accounting, and treatment stacking. Do not recast them as a federal refund statute or as proof two devices are interchangeable.
Question worksheet and labeled fictional examples
Use the table as a copy-out worksheet, not as a ranking and not as a finding of equivalence. Columns are the patient question; what public evidence can support asking it; what explanation to request; which clinician or role owns the answer; and what remains unresolved if the field is blank. Leave unknown fields unknown. Hypothetical rows are labeled fictional, internally consistent, and not real cases. They are not comparative treatment evidence, and they do not authorize transferring settings from one machine to another.
The first four rows cover scheduled identity; substitute identity and indication match; clinician reassessment and consent for the device actually used; and written package terms. One fictional row keeps the same manufacturer family but a different named model. One fictional row is a different modality: a scheduled laser versus an intense pulsed light system, without asserting that IPL is a laser.
| Patient question | What public evidence can support asking it | What explanation to request | Which clinician or role owns the answer | What remains unresolved if the field is blank |
|---|---|---|---|---|
| Scheduled-device identity: what trade name, model, and, if known, 510(k) or other clearance identifier named the machine I was scheduled to receive? | 21 CFR 807.92(a)(2) requires a 510(k) summary to name the device by trade or proprietary name if applicable, common or usual name, and classification name if known. Paragraph (a)(1) is submitter contact information, not the device name. | Request the manufacturer, commercial trade name, model, and, if known, 510(k) or other clearance identifier of the scheduled console. If a K-number is unknown, leave it unknown. | The treating clinician or named supervising physician who assessed the original intervention. | Scheduled identity is unknown. Remaining sessions cannot be treated as a continuation of a named device. |
| Substitute-device identity and indication match: what trade name and model name the replacement, and do its intended-use and patient-population statements match the planned indication and population context? | 21 CFR 807.92(a)(5) requires intended use, including patient population where appropriate. 21 CFR 807.92(a)(6) requires a technological-characteristics comparison, including energy source. 21 CFR 807.97 states that substantial equivalence does not denote official approval. | Request the substitute’s commercial name, model, and, if a public summary exists, its intended-use and patient-population language. Ask whether those fields match the planned indication, or whether the match is unknown. Do not accept a shared wavelength band as a substitute for those fields. | The treating clinician who will use the substitute, or the named prescribing practitioner. | Indication match is unknown. Two separately named devices are not interchangeable by default. |
| Reassessment and consent: who will reassess candidacy for the device that will actually be used, and will consent be sought for that specific intervention? | AMA Opinion 2.1.1 treats consent as agreement to a specific medical intervention and tells physicians to present nature, purpose, burdens, risks, expected benefits of all options including forgoing treatment, and to document the conversation. The FDA Aesthetic (Cosmetic) Devices page advises discussing candidacy, benefits, risks, and the provider’s training with the procedure under consideration. | Request the name and role of the responsible clinician, a candidacy conversation for the substitute device, and documented consent for that intervention rather than reuse of the original booking paperwork. | The named responsible clinician. AMA Opinion 2.1.1 addresses physicians; if a non-physician will operate the device, still require the responsible clinician to be named. This article does not invent a universal operator-license rule. | Consent for the device actually used is not established. Operator training on the substitute remains unconfirmed because it was not named. |
| Written package terms: if I decline the substitute, what written language governs unused sessions, expiration, pause, credit, or substitution? | Package terms are a written-contract field. This article does not treat 16 CFR Part 429 as an automatic in-clinic cancellation or refund right, and it does not advise that a named clinic must refund unused sessions. | Request the signed package language on unused sessions, expiration, substitution, and pause. If a clause is missing, record it as blank. | Clinic practice manager or other administrative owner of unused-session terms, which is a separate role from the treating clinician. | Unused-session terms remain unknown. Do not assume a refund, credit, or forfeiture. |
| Hypothetical Scenario A (labeled fictional): scheduled on Fictional System Alpha, then offered Fictional System Beta from the same manufacturer family, a different named model. | 21 CFR 807.92 requires each named device’s summary to carry its own trade name, intended use including patient population where appropriate, and technological characteristics including energy source. A shared manufacturer family is not a finding of equivalence. | Ask the clinician to name both models and to say whether Beta’s intended-use and patient-population language, if a public summary exists, matches the planned indication, or that the match is unknown. Do not transfer settings from Alpha to Beta. | The named supervising clinician for the session that would use System Beta. | Same-family substitution is still a different named device. Identity, indication match, and consent for Beta remain unresolved until documented. |
| Hypothetical Scenario B (labeled fictional): scheduled on Fictional Laser, an 810 nm diode named for hair reduction, then offered Fictional Pulsed Light, a broadband intense pulsed light system, because the laser is down. | 21 CFR 807.92 treats each named device separately. 21 CFR 801.4 ties intended use to labeling persons’ objective intent. Intense pulsed light is not a laser; this row does not recast the published laser-versus-IPL comparison. | Ask the clinician to disclose that the substitute is not a laser, to name the IPL system, and to obtain consent for that modality if it is the intervention actually offered. Do not assert session-count equivalence or interchangeability. | The named treating clinician for the IPL offer. | This is a modality change, not leftover laser sessions. Consent and indication match for the IPL system remain unknown until documented. |
If any worksheet field cannot be filled from documentation the clinic actually produces, treat it as unknown rather than as an assumed yes. Unknown identity, an unnamed consent owner, or blank package terms are unresolved choices. This article does not instruct the reader to operate, repair, or set any device, and it does not convert a blank cell into a refund right.
Sources
21 CFR 807.92 — Content and format of a 510(k) summary (eCFR, unofficial; Title 21 display current as of 2026-09-04, last amended 2026-08-31: 510(k) summary must include device name, predicate, description, intended use including patient population where appropriate, and technological characteristics including energy source).
21 CFR 807.97 — Misbranding by reference to premarket notification (eCFR, unofficial: substantial-equivalence determination does not denote official approval; representing premarket notification as official approval is misleading and constitutes misbranding).
21 CFR 807.81 — When a premarket notification submission is required (eCFR, unofficial: manufacturer filing trigger for a significant change to a device in commercial distribution, including the PCCP exception under section 515C).
21 CFR 801.4 — Meaning of intended uses (eCFR, unofficial: intended uses are the objective intent of persons legally responsible for labeling; knowledge of health-care-provider off-label use is not, by itself, manufacturer new-use intent).
U.S. Food and Drug Administration: Deciding When to Submit a 510(k) for a Change to an Existing Device (CDRH/CBER guidance, October 25, 2017, nonbinding: should means suggested or recommended; indications for use include patient population; A.1.4 and direction-for-use examples address new patient population, new procedural technique, and different duration or frequency).
U.S. Food and Drug Administration: Premarket Notification 510(k) (explainer, content current as of August 22, 2024: substantial equivalence does not require the new and predicate devices to be identical).
American Medical Association: Code of Medical Ethics Opinion 2.1.1 — Informed Consent (ethics guidance for physicians: consent is agreement to a specific medical intervention; present diagnosis when known, nature and purpose, burdens, risks, and expected benefits of all options including forgoing treatment; document the conversation).
U.S. Food and Drug Administration: Aesthetic (Cosmetic) Devices (consumer page, content current as of December 7, 2022: discuss candidacy, benefits, risks, and provider training and experience with the procedure).
